<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693849</url>
  </required_header>
  <id_info>
    <org_study_id>iSPOT-D</org_study_id>
    <nct_id>NCT00693849</nct_id>
  </id_info>
  <brief_title>International Study to Predict Optimised Treatment - in Depression</brief_title>
  <acronym>iSPOT-D</acronym>
  <official_title>International Study to Predict Optimised Treatment - in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BRC Operations Pty. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BRC Operations Pty. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to identify genetic, physical (brain) and psychological (cognitive)
      markers (or combinations of them) that predict specific response to a range of
      antidepressants treatment (Escitalopram, Venlafaxine, Sertraline) in patients diagnosed with
      major depressive disorder. This study is focused on outcomes which may impact on how
      &quot;personalised medicine&quot; is implemented in depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomised (effectiveness) study (ie. comparison of active treatments)
      to identify genetic markers, brain function, brain structure, and psychological and cognitive
      indicators (or a combination of markers) in MDD subjects versus healthy controls.
      Approximately 2,016 subjects with major depressive disorder (MDD) across multiple
      international sites (USA, Canada, UK, South Africa, New Zealand, The Netherlands and
      Australia) will be randomised to one of three approved and effective treatment arms:

      Treatment A Escitalopram. Treatment B Sertraline. Treatment C Venlafaxine XR.

      A group of matched healthy controls (n = 672) will also be enrolled.

      Subjects will be asked to attend the testing facility on two separate occasions; for
      Pre-treatment (Pre-Tx) and at 8 weeks post initiation of treatment. The
      assessments/procedures at Pre-Tx and Week 8 include: Baseline a clinical work-up, blood
      collection for genetic analyses, cognitive testing and electrical brain functioning
      (EEG/ERP). Structural and functional data MRI data will be collected in ten percent (10%) of
      participants.

      On Day 4 and Weeks 2, 4, 6, 12, 16, 24 and 52 Subjects will be contacted by phone and asked
      to complete 2 questionnaires via the internet.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether the genetic-brain-cognition function markers (or combination of markers) 'normalise' with acute drug treatment in MDD</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether markers of acute treatment prediction are also predictive of functional outcome over 6-12 months.</measure>
    <time_frame>52-weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2688</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Escitalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Venlafaxine-XR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy matched controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10 mg/day as a single dose, increased to max 20 mg/day</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>50 mg/day as a single dose, increased to max of 200 mg/day</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine-XR</intervention_name>
    <description>75 mg/day given once daily; increased to 150-225 mg/day</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Effexor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet DSM-IV criteria for primary diagnosis of MDD.

          -  HAM-D17 score of â‰¥ 16.

          -  18-65 years age-range

          -  Subjects with English or Dutch literacy and fluency.

          -  Written, informed consent.

        Exclusion Criteria:

          -  Presence of suicidal ideations and/or tendencies (as determined by a score &gt;12 on
             Section C, Suicidality, of the MINI Plus), Bipolar I-III, psychosis, primary eating
             disorders, Post Traumatic Stress Disorder (PTSD), Obsessive Compulsive Disorder (OCD),
             Post-Natal Depression as well as any Axis II personality disorders as diagnosed using
             the MINI Plus or by a health care professional.

          -  Pregnancy and women of child bearing potential who are not taking a medically accepted
             form of contraception and are at risk of becoming pregnant during the study.

          -  Breastfeeding.

          -  Known contra-indication or intolerance to the use of Escitalopram, Sertraline or
             Venlafaxine XR as defined in the product package insert for each drug (including
             previous treatment failure at the highest recommended dose).

          -  Use of any psychological or counselling therapy or antidepressant/CNS drug which
             cannot be washed out prior to participation and eliminated until after Week 8 or
             discontinuation.

          -  Use of any medication which is known to be contraindicated with Escitalopram,
             Sertraline, or Venlafaxine XR (refer to the product package insert for each drug).

          -  Known medical condition, disease or neurological disorder which might, in the opinion
             of investigator/s, interfere with the assessments to be made in the study or put
             subjects at increased risk when exposed to optimal doses of the drug treatment.

          -  History of head injury with loss of consciousness for at least 10 minutes.

          -  Recent/current substance dependence (as defined in Section K of the Mini Plus as per a
             6 months period and/or alcoholism) in the past six months.

          -  Participation in an investigational study within four months of the baseline visit in
             which subjects have received an experimental drug/device that could affect the primary
             end points of this study.

          -  Subjects who, in the opinion of the investigator, have a severe impediment to vision,
             hearing and/or hand movement, which is likely to interfere with their ability to
             complete the test batteries.

          -  Subjects who, in the opinion of the investigator, are unable and/or unlikely to
             comprehend and follow the study procedures and instructions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Harris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brain Dynamics Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara A. Cohen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Healing the Human Spirit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Russell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Auckland, New Zealand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Debattista, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Con Stough, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swinburne University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Wallis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brain Health Lab</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harbans Multani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanti Clinical Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jayashri Kulkarni, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred and Delmont Private Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Wilson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.D.D. Treatment Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kamran Fallahpour, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brain Resource Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larry Hirshberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NeuroDevelopment Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martijn Arns, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brainclinics Diagnostics B.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona Ismail, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brain Resource Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Fitzgerald, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Clark, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flinders University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger deBeus, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skyland Behavioral Health Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Bruce, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri, St. Louis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Subhdeep Virk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Usherwood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brain Dynamics Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>XiaoLei Yu Baran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Radu V Saveanu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanti Clinical Trials</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>A.D.D. Treatment Center</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Veteran Affairs/Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Center for Healing the Human Spirit</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Missouri - St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Brain Resource Center</name>
      <address>
        <city>Englewood Cliffs</city>
        <state>New Jersey</state>
        <zip>07632</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Brain Resource Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Skyland Behavioral Health Associates , P.A.</name>
      <address>
        <city>Ashville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>NeuroDevelopment Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Brain Dynamics Centre</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Flinders University</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Delmont Private Hospital</name>
      <address>
        <city>Glen Iris</city>
        <state>Victoria</state>
        <zip>3146</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Swinburne University</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3122</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Brainclinics Diagnostics B.V.</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6524 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tabitha Iseger</last_name>
      <email>Tabitha@brainclinics.com</email>
    </contact>
    <investigator>
      <last_name>Martijn Arns, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Auckland</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Brain Health Lab</name>
      <address>
        <city>Johannesburg</city>
        <state>Guatang</state>
        <zip>2191</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ANZCTR.org.au/ACTRN12608000476336.aspx</url>
    <description>Australian New Zealand Clinical Trials Registry</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>CNS</keyword>
  <keyword>iSPOT</keyword>
  <keyword>MDD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

